Short-chain fructo-oligosaccharide and inulin modulate inflammatory responses and microbial communities in Caco2-bbe cells and in a mouse model of intestinal injury

Journal of Nutrition

Volumn 144, Issue 11, 2014, Pages 1725-1733

  Johnson Henry, Kathene C ^a   Pinnell, Lee J ^a   Waskow, Alexandra M ^c   Irrazabal, Thergiory ^b   Martin, Alberto ^b   Hausner, Martina ^c   Sherman, Philip M ^a,b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c RYERSON UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; FRUCTOSE OLIGOSACCHARIDE; INTERLEUKIN 10; INTERLEUKIN 8; INULIN; OCCLUDIN; PREBIOTIC AGENT; TIGHT JUNCTION PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; OLIGOSACCHARIDE;

ACTIN POLYMERIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CACO 2 CELL LINE; CELL MEMBRANE PERMEABILITY; CITROBACTER RODENTIUM; CONTROLLED STUDY; ENTEROHEMORRHAGIC ESCHERICHIA COLI; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATORY BOWEL DISEASE; INTESTINE INJURY; MICROBIAL COMMUNITY; MICROBIOME; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; C57BL MOUSE; CHEMISTRY; COLITIS; COMPLICATION; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI O157; FECES; INFLAMMATION; MICROBIOLOGY;

ANIMALIA; CITROBACTER RODENTIUM; ESCHERICHIA COLI; MUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CACO-2 CELLS; CITROBACTER RODENTIUM; COLITIS; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI O157; FECES; FEMALE; HUMANS; INFLAMMATION; INULIN; MICE; MICE, INBRED C57BL; OLIGOSACCHARIDES; PREBIOTICS;

EID: 84916894577     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.114.195081     Document Type: Article

References (58)

1. Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, Sherman PM, Mayer EA. An update on the use and investigation of probiotics in health and disease. Gut 2013;62:787-96.
2. Kellow NJ, Coughlan MT, Reid CM. Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials. Br J Nutr 2014;111:1147-61.
3. Roberfroid M. Prebiotics: the concept revisited. J Nutr 2007;137:830S-7S.
4. Flint HJ, Scott KP, Duncan SH, Louis P, Forano E. Microbial degradation of complex carbohydrates in the gut. Gut Microbes 2012;3:289-306.
5. Sherman PM, Cabana M, Gibson GR, Koletzko BV, Neu J, Veereman-Wauters G, Ziegler EE,WalkerWA. Potential roles and clinical utility of prebiotics in newborns, infants, and children: proceedings from a global prebiotic summit meeting, New York City, June 27-28, 2008. J Pediatr 2009;155:S61-70.
6. Mäkeläinen H, Saarinen M, Stowell J, Rautonen N, Ouwehand AC. Xylo-oligosaccharides and lactitol promote the growth of Bifidobacterium lactis and Lactobacillus species in pure cultures. Benef Microbes 2010;1:139-48.
7. Guarner F. Prebiotics in inflammatory bowel diseases. Br J Nutr 2007;98(Suppl 1):S85-9.
8. Mariat D, Firmesse O, Levenez F, Guimaraes V, Sokol H, Dore J, Corthier G, Furet JP. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol 2009;9:123.
9. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012;13:R79.
10. Wacklin P, Kaukinen K, Tuovinen E, Collin P, Lindfors K, Partanen J, Maki M, Matto J. The duodenal microbiota composition of adult celiac disease patients is associated with the clinical manifestation of the disease. Inflamm Bowel Dis 2013;19:934-41.
11. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006;444:1022-3.
12. Vulevic J, Juric A, Tzortzis G, Gibson GR. A mixture of transgalactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. J Nutr 2013;143:324-31.
13. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 2010;7:503-14.
14. Sherman PM, Hassall E, Fagundes-Neto U, Gold BD, Kato S, Koletzko S, Orenstein S, Rudolph C, Vakil N, Vandenplas Y. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol 2009;104:1278-95.
15. Rodrigues DM, Sousa AJ, Johnson-Henry KC, Sherman PM, Gareau MG. Probiotics are effective for the prevention and treatment of Citrobacter rodentium-induced colitis in mice. J Infect Dis 2012; 206:99-109.
16. Martin FP, Wang Y, Sprenger N, Yap IK, Rezzi S, Ramadan Z, Pere-Trepat E, Rochat F, Cherbut C, van Bladeren P, et al. Top-down systems biology integration of conditional prebiotic modulated transgenomic interactions in a humanized microbiome mouse model. Mol Syst Biol 2008;4:205.
17. Jantscher-Krenn E, Zherebtsov M, Nissan C, Goth K, Guner YS, Naidu N, Choudhury B, Grishin AV, Ford HR, Bode L. The human milk oligosaccharide disialyllacto-N-tetraose prevents necrotising enterocolitis in neonatal rats. Gut 2012;61:1417-25.
18. Koleva PT, Valcheva RS, Sun X, Ganzle MG, Dieleman LA. Inulin and fructo-oligosaccharides have divergent effects on colitis and commensal microbiota in HLA-B27 transgenic rats. Br J Nutr 2012;108:1633-43.
19. Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2008;28:385-96.
20. Steed H, Macfarlane GT, Macfarlane S. Prebiotics, synbiotics and inflammatory bowel disease. Mol Nutr Food Res 2008;52:898-905.
21. Brownawell AM, Caers W, Gibson GR, Kendall CW, Lewis KD, Ringel Y, Slavin JL. Prebiotics and the health benefits of fiber: current regulatory status, future research, and goals. J Nutr 2012; 142:962-74.
22. Macfarlane S, Macfarlane GT, Cummings JH. Review article: prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther 2006;24:701-14.
23. Petersen A, Bergstrom A, Andersen JB, Hansen M, Lahtinen SJ, Wilcks A, Licht TR. Analysis of the intestinal microbiota of oligosaccharide fed mice exhibiting reduced resistance to Salmonella infection. Benef Microbes 2010;1:271-81.
24. Ho NK, Hawley SP, Ossa JC, Mathieu O, Tompkins TA, Johnson-Henry KC, Sherman PM. Immune signalling responses in intestinal epithelial cells exposed to pathogenic Escherichia coli and lactic acidproducing probiotics. Benef Microbes 2013;4:195-209.
25. Wine E, Gareau MG, Johnson-Henry K, Sherman PM. Strain-specific probiotic (Lactobacillus helveticus) inhibition of Campylobacter jejuni invasion of human intestinal epithelial cells. FEMS Microbiol Lett 2009;300:146-52.
26. Wine E, Shen-Tu G, Gareau MG, Goldberg HA, Licht C, Ngan BY, Sorensen ES, Greenaway J, Sodek J, Zohar R, et al. Osteopontin mediates Citrobacter rodentium-induced colonic epithelial cell hyperplasia and attaching-effacing lesions. Am J Pathol 2010;177: 1320-32.
27. Donato KA, Gareau MG, Wang YJ, Sherman PM. Lactobacillus rhamnosus GG attenuates interferon-{gamma} and tumour necrosis factor-alpha-induced barrier dysfunction and pro-inflammatory signalling. Microbiology 2010;156:3288-97.
28. Johnson-Henry KC, Donato KA, Shen-Tu G, Gordanpour M, Sherman PM. Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function. Infect Immun 2008;76:1340-8.
29. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, PfafflMW, Shipley GL, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611-22.
30. Prokopec SD, Buchner NB, Fox NS, Chong LC, Mak DY, Watson JD, Petronis A, Pohjanvirta R, Boutros PC. Validating reference genes within a mouse model system of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) toxicity. Chem Biol Interact 2013;205:63-71.
31. Petersen A, Heegaard PM, Pedersen AL, Andersen JB, Sorensen RB, Frokiaer H, Lahtinen SJ, Ouwehand AC, Poulsen M, Licht TR. Some putative prebiotics increase the severity of Salmonella enterica serovar Typhimurium infection in mice. BMC Microbiol 2009;9:245.
32. Lebeer S, Verhoeven TL, Claes IJ, De Hertogh G, Vermeire S, Buyse J, Van Immerseel F, Vanderleyden J, De Keersmaecker SC. FISH analysis of Lactobacillus biofilms in the gastrointestinal tract of different hosts. Lett Appl Microbiol 2011;52:220-6.
33. Kouadjo KE, Nishida Y, Cadrin-Girard JF, Yoshioka M, St-Amand J. Housekeeping and tissue-specific genes in mouse tissues. BMC Genomics 2007;8:127.
34. Gareau MG, Wine E, Rodrigues DM, Cho JH, Whary MT, Philpott DJ, Macqueen G, Sherman PM. Bacterial infection causes stress-induced memory dysfunction in mice. Gut 2011;60:307-17.
35. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
36. Rüssmann H, Feydt-Schmidt A, Adler K, Aust D, Fischer A, Koletzko S. Detection of Helicobacter pylori in paraffin-embedded and in shockfrozen gastric biopsy samples by fluorescent in situ hybridization. J Clin Microbiol 2003;41:813-5.
37. Amann RI, Ludwig W, Schleifer KH. Phylogenetic identification and in situ detection of individual microbial cells without cultivation. Microbiol Rev 1995;59:143-69.
38. Manz W, Amann R, Szewzyk R, Szewzyk U, Stenstrom TA, Hutzler P, Schleifer KH. In situ identification of Legionellaceae using 16S rRNAtargeted oligonucleotide probes and confocal laser scanning microscopy. Microbiology 1995;141:29-39.
39. Amann RI, Binder BJ, Olson RJ, Chisholm SW, Devereux R, Stahl DA. Combination of 16S rRNA-targeted oligonucleotide probes with flow cytometry for analyzing mixed microbial populations. Appl Environ Microbiol 1990;56:1919-25.
40. Roller C, Wagner M, Amann R, Ludwig W, Schleifer KH. In situ probing of gram-positive bacteria with high DNA G + C content using 23S rRNA-targeted oligonucleotides. Microbiology 1994;140:2849-58.
41. Platform independent ImageJ 1.47. Available from: http://rsbweb.nih. gov/ij/download.html.
42. Fernandes J, Wang A, Su W, Rozenbloom SR, Taibi A, Comelli EM, Wolever TM. Age, dietary fiber, breath methane, and fecal short-chain fatty acids are interrelated in Archaea-positive humans. J Nutr 2013;143:1269-75.
43. McKeel R, Douris N, Foley PL, Feldman SH. Comparison of an espB gene fecal polymerase chain reaction assay with bacteriologic isolation for detection of Citrobacter rodentium infection in mice. Comp Med 2002;52:439-44.
44. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8.
45. Croxen MA, Finlay BB. Molecular mechanisms of Escherichia coli pathogenicity. Nat Rev Microbiol 2010;8:26-38.
46. Sherman PM, Johnson-Henry KC, Yeung HP, Ngo PS, Goulet J, Tompkins TA. Probiotics reduce enterohemorrhagic Escherichia coli O157:H7-and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun 2005;73:5183-8.
47. Shoaf K, Mulvey GL, Armstrong GD, Hutkins RW. Prebiotic galactooligosaccharides reduce adherence of enteropathogenic Escherichia coli to tissue culture cells. Infect Immun 2006;74:6920-8.
48. Shoaf-Sweeney KD, Hutkins RW. Adherence, anti-adherence, and oligosaccharides preventing pathogens from sticking to the host. Adv Food Nutr Res 2009;55:101-61.
49. Blottière HM, Buecher B, Galmiche JP, Cherbut C. Molecular analysis of the effect of short-chain fatty acids on intestinal cell proliferation. Proc Nutr Soc 2003;62:101-6.
50. Peng L, He Z, Chen W, Holzman IR, Lin J. Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res 2007;61:37-41.
51. Ten Bruggencate SJ, Bovee-Oudenhoven IM, Lettink-Wissink ML, Van der Meer R. Dietary fructo-oligosaccharides increase intestinal permeability in rats. J Nutr 2005;135:837-42.
52. Olmstead S, Wolfson D, Meiss D, Ralston R. Understanding prebiotics. 2008 [cited 2013 August 8]. Available from: http://chriskresser.com/ articles/prebiotics.pdf.
53. Zenhom M, Hyder A, de Vrese M, Heller KJ, Roeder T, Schrezenmeir J. Prebiotic oligosaccharides reduce proinflammatory cytokines in intestinal Caco-2 cells via activation of PPARgamma and peptidoglycan recognition protein 3. J Nutr 2011;141:971-7.
54. Boehm G, Moro G. Structural and functional aspects of prebiotics used in infant nutrition. J Nutr 2008;138:1818S-28S.
55. Lomax AR, Calder PC. Prebiotics, immune function, infection and inflammation: a review of the evidence. Br J Nutr 2009;101:633-58.
56. Donovan SM, Wang M, Li M, Friedberg I, Schwartz SL, Chapkin RS. Host-microbe interactions in the neonatal intestine: role of human milk oligosaccharides. Adv Nutr 2012;3:450S-5S.
57. Makras L, Van Acker G, De Vuyst L. Lactobacillus paracasei subsp. paracasei 8700:2 degrades inulin-type fructans exhibiting different degrees of polymerization. Appl Environ Microbiol 2005;71: 6531-7.
58. Bäckhed F, Fraser CM, Ringel Y, Sanders ME, Sartor RB, Sherman PM, Versalovic J, Young V, Finlay BB. Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe 2012;12:611-22.